{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:11:12Z","timestamp":1788502272106,"version":"build-2803163510"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s10147-024-02570-8","type":"journal-article","created":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T04:01:59Z","timestamp":1718856119000},"page":"1074-1080","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Effectiveness and safety of primary prophylaxis with G-CSF during chemotherapy for invasive breast cancer: a systematic review and meta-analysis from Clinical Practice Guidelines for the Use of G-CSF 2022"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0277-8196","authenticated-orcid":false,"given":"Kazuki","family":"Nozawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhiro","family":"Yoshinami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takamichi","family":"Yokoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Tsuchihashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiki","family":"Ichihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Susumu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munetaka","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Motohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamoru","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eishi","family":"Baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuaki","family":"Ochi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Kubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keita","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Kamiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Nakao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Tamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitomi","family":"Nishimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshimi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"issue":"1","key":"2570_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/CAAC.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS et al (2023) Cancer statistics, 2023. CA Cancer J Clin 73(1):17\u201348. https:\/\/doi.org\/10.3322\/CAAC.21763","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"2570_CR2","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1002\/CNCR.21847","volume":"106","author":"NM Kuderer","year":"2006","unstructured":"Kuderer NM, Dale DC, Crawford J et al (2006) Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer 106(10):2258\u20132266. https:\/\/doi.org\/10.1002\/CNCR.21847","journal-title":"Cancer"},{"issue":"2","key":"2570_CR3","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/j.1524-4733.2007.00242.x","volume":"11","author":"A Eldar-Lissai","year":"2008","unstructured":"Eldar-Lissai A, Cosler LE, Culakova E et al (2008) Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health. 11(2):172\u2013179. https:\/\/doi.org\/10.1111\/j.1524-4733.2007.00242.x","journal-title":"Value Health."},{"issue":"15","key":"2570_CR4","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1016\/j.ejca.2006.05.002","volume":"42","author":"MS Aapro","year":"2006","unstructured":"Aapro MS, Cameron DA, Pettengell R et al (2006) EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 42(15):2433\u20132453. https:\/\/doi.org\/10.1016\/j.ejca.2006.05.002","journal-title":"Eur J Cancer"},{"issue":"8","key":"2570_CR5","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1200\/JCO.2003.09.081","volume":"21","author":"ML Citron","year":"2003","unstructured":"Citron ML, Berry DA, Cirrincione C et al (2003) Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741\/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 21(8):1431\u20131439","journal-title":"J Clin Oncol"},{"key":"2570_CR6","unstructured":"Morizane T, Yoshida M, Kojimahara N et al (2014) Minds handbook for clinical practice guideline development 2014. Japan Council for Quality Health Care, Tokyo. https:\/\/minds.jcqhc.or.jp\/s\/developer_manual (in Japanese)"},{"key":"2570_CR7","unstructured":"Kojimahara N, Nakayama T, Morizane T et al (2017) Minds manual for guideline development 2017. Japan Council for Quality Health Care, Tokyo. https:\/\/minds.jcqhc.or.jp\/s\/developer_manual (in Japanese)"},{"key":"2570_CR8","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00520-018-4408-6","volume":"27","author":"M Clemons","year":"2019","unstructured":"Clemons M, Mazzarello S, Hilton J et al (2019) Feasibility of using a pragmatic trials model to compare two primary febrile neutropenia prophylaxis regimens(ciprofloxacin versus G-CSF) in patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer(REaCT-TC). Support Care Cancer 27:1345\u20131354","journal-title":"Support Care Cancer"},{"key":"2570_CR9","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.clbc.2018.04.001","volume":"18","author":"KA Cadoo","year":"2018","unstructured":"Cadoo KA, Kaufman PA, Seidman AD et al (2018) Phase 2 study of dose-dense doxorubicin and cyclophosphamide followed by eribulin mesylate with or without prophylactic growth factor for adjuvant treatment of early-stage human epidermal growth factor receptor 2-negative breast cancer. Clin Breast Cancer 18:433-440.e1","journal-title":"Clin Breast Cancer"},{"key":"2570_CR10","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1200\/JCO.1995.13.7.1564","volume":"13","author":"B Chevallier","year":"1995","unstructured":"Chevallier B, Chollet P, Merrouche Y et al (1995) Lenograstim prevents morbidity from intensive induction chemotherapy in the treatment of inflammatory breast cancer. J Clin Oncol 13:1564\u20131571","journal-title":"J Clin Oncol"},{"key":"2570_CR11","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00520-014-2597-1","volume":"23","author":"Y Kosaka","year":"2015","unstructured":"Kosaka Y, Rai Y, Masuda N et al (2015) Phase III placebo-controlled, double-blind, randomized trial of pegfilgrastim to reduce the risk of febrile neutropenia in breast cancer patients receiving docetaxel\/cyclophosphamide chemotherapy. Support Care Cancer 23:1137\u20131143","journal-title":"Support Care Cancer"},{"key":"2570_CR12","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.critrevonc.2009.05.002","volume":"72","author":"W Brugger","year":"2009","unstructured":"Brugger W, Bacon P, Lawrinson S et al (2009) Neutrophil recovery in elderly breast cancer patients receiving adjuvant anthracycline-containing chemotherapy with pegfilgrastim support. Crit Rev Oncol Hematol 72:265\u2013269","journal-title":"Crit Rev Oncol Hematol"},{"key":"2570_CR13","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.critrevonc.2006.12.007","volume":"64","author":"G Romieu","year":"2007","unstructured":"Romieu G, Clemens M, Mahlberg R et al (2007) Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial. Crit Rev Oncol Hematol 64:64\u201372","journal-title":"Crit Rev Oncol Hematol"},{"key":"2570_CR14","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1200\/JCO.2005.09.102","volume":"23","author":"CL Vogel","year":"2005","unstructured":"Vogel CL, Wojtukiewicz MZ, Carroll RR et al (2005) First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study. J Clin Oncol 23:1178\u20131184","journal-title":"J Clin Oncol"},{"key":"2570_CR15","doi-asserted-by":"publisher","first-page":"6908","DOI":"10.1200\/JCO.2005.03.099","volume":"23","author":"P Papaldo","year":"2005","unstructured":"Papaldo P, Lopez M, Marolla P et al (2005) Impact of five prophylactic filgrastim schedules on hematologic toxicity in early breast cancer patients treated with epirubicin and cyclophosphamide. J Clin Oncol 23:6908\u20136918","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02570-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-024-02570-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-024-02570-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,25]],"date-time":"2024-07-25T05:30:49Z","timestamp":1721885449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-024-02570-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":15,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["2570"],"URL":"https:\/\/doi.org\/10.1007\/s10147-024-02570-8","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]},"assertion":[{"value":"20 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"<i>Y<\/i>.<i>O<\/i>. received honoraria from Daiichi-Sankyo, Pfizer, Chugai, Lilly and Kyowa Kirin. <i>T<\/i>.<i>Y<\/i>. received honoraria from Kyowa-Kirin, Pfizer, Chugai, Eli Lilly, MSD, AstraZeneca and Eisai. <i>K<\/i>.<i>T<\/i>. received honoraria from Ono, Chugai, Taiho and Novartis. <i>E<\/i>.<i>I<\/i>. received honoraria from Eli Lilly, and research funding from MSD, Ono, Janssen Pharma and Takeda. <i>Y<\/i>.<i>M<\/i>. received honoraria from Ono, MSD, Takeda, Eisai and Bristol Myers Squibb, and research funding from MSD and Ono. <i>S<\/i>.<i>Y<\/i>. received research funding from Otsuka. <i>D<\/i>.<i>M<\/i>. received honoraria from Janssen, Nippon Shinyaku, Eisai, Mundipharma, Kyowa Kirin, Chugai, Zenyaku, MSD, SymBio, Sanofi, AbbVie, Takeda, Astra Zeneca and Bristol Myers Squibb, and research funding from Biopharma, Novartis, Kyowa Kirin, Ono, Chugai, Janssen, Takeda, Otsuka, Sanofi, Astellas, Bristol Myers Squibb, AbbVie, Eisai, MSD, Taiho and Astra Zeneca. <i>T<\/i>.<i>M<\/i>. received honoraria from Astra Zeneca, Chugai and Myriadgenetics. <i>E<\/i>.<i>B<\/i>. received honoraria from Chugai, and Daiichi-Sankyo, and research funding from Taiho and Chugai. <i>T<\/i>.<i>KU<\/i>. received honoraria from Chugai. <i>T<\/i>.<i>KI<\/i>. received honoraria from Sanofi. <i>S<\/i>.<i>N<\/i>. received honoraria from Kyowa Kirin. <i>A<\/i>.<i>S<\/i>. received honoraria and scholarship donation from Chugai and Taiho. <i>T<\/i>.<i>T<\/i>. received honoraria from Daiichi-Sankyo, Chugai and Eli Lilly. Other authors declare that there are no conflicts of interest associated with this manuscript. The other authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Formal consent was not required for this type of study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"All authors consented to the publication of this study.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}